Compare NVEC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | MIST |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.9M | 163.2M |
| IPO Year | 1996 | N/A |
| Metric | NVEC | MIST |
|---|---|---|
| Price | $63.72 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 59.9K | ★ 9.8M |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $24,784,396.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.50 | $0.63 |
| 52 Week High | $88.50 | $3.06 |
| Indicator | NVEC | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 37.08 |
| Support Level | $70.12 | $2.00 |
| Resistance Level | $73.42 | $2.22 |
| Average True Range (ATR) | 2.51 | 0.32 |
| MACD | -0.51 | -0.09 |
| Stochastic Oscillator | 2.85 | 25.17 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).